Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com

1. WEIKANG BIO-TECHNOLGY GROUP CO., INC Investor Presentation 2010 OTCBB: WKBT www.weikangbio.com

2. In accordance with the 1995 Securities Litigation Reform Act of the "exemption" meaning, this statement documents contain "forward-looking statements". This statement related to understand and unknown risks, uncertainties and other factors will cause the company’s statement not match by the results, in which including sales and regional economic conditions and competitive conditions, customer relation Changes, access to capital, the difficulty of promoting new products, existing products market conditions, customers for the existing and new product awareness and other factors. Relevantly, the company believed that the results is reasonable in this forward-looking statements ， but can not guarantee that the forecast entirely correct. There is no duty that company to update the forward-looking information contained in this statements. Safe Harbor Statement

20. $m Increasing Revenue

21. $m Strong Gross Margin

22. $m Increasing Net Income

23. USD in millions Dec. 31 2009 Mar. 31 2010 Cash and Equivalents $11.4 $18.1 11.7 19.5 Current Liabilities 10.5 10.8 Long-Term Debt 0.0 0.0 Shareholder's Equity 23.4 31.1 Current Assets Balance Sheet Highlights

24. Attractive Valuation Company Ticker (Exch) Price (6/8/10) Market Cap (mm) Revenues 2009 (mm) Net Income 2009 (mm) Y/Y Net Income % Y/Y revenue % PE (TTM) Weikang Bio-Technology WKBT (OTCBB) $2.79 $76.45 $47.4 $15.6 116.67% 270.31% 4.5 Biostar Pharmaceuticals BSPM (OTCBB) $3.23 $83.42 $53.3 $10.5 56.95% 57.24% 9.8 Renhuang Pharmaceutical RHGP (OTCBB) $2.00 $74.47 $43.4 $14.8 43.69% 3.67% 4.7 American Oriental Bioengineering AOB (NYSE) $2.72 $213.18 $296.1 $41.4 -13.39% 11.90% 5.1 China SkyOne Medical CSKI (NASDAQ) $11.33 $190.23 $130.1 $34.4 19.40% 41.72% 5.5 Tianyin Pharmaceutical Company TPI (AMEX) $2.67 $71.67 $42.8 $7.9 32.50% 28.18% 7.9 China Pharma CPHI (AMEX) $2.67 $115.58 $61.7 $20.3 13.46% 21.05% 5.6 Simcere Pharmaceuticals SCR (NYSE) $8.13 $447.27 $270.9 $17.5 -65.89% 6.24% 22.0 Average 12.4% 24.3% 6.4